{"id":"https://openalex.org/W2017898700","doi":"https://doi.org/10.1002/jps.2600821005","title":"Comparative Pharmacokinetics of Free Muramyl Tripeptide Phosphatidyl Ethanolamine (MTP-PE) and Liposomal MTP-PE","display_name":"Comparative Pharmacokinetics of Free Muramyl Tripeptide Phosphatidyl Ethanolamine (MTP-PE) and Liposomal MTP-PE","publication_year":1993,"publication_date":"1993-10-01","ids":{"openalex":"https://openalex.org/W2017898700","doi":"https://doi.org/10.1002/jps.2600821005","mag":"2017898700","pmid":"https://pubmed.ncbi.nlm.nih.gov/8254500"},"language":"en","primary_location":{"id":"doi:10.1002/jps.2600821005","doi":"https://doi.org/10.1002/jps.2600821005","is_oa":false,"landing_page_url":"https://doi.org/10.1002/jps.2600821005","pdf_url":null,"source":{"id":"https://openalex.org/S130661733","display_name":"Journal of Pharmaceutical Sciences","issn_l":"0022-3549","issn":["0022-3549","1520-6017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Sciences","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083980759","display_name":"Brigitte Gay","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Brigitte Gay","raw_affiliation_strings":["Ciba-Geigy Limited, Oncology and Virology Department, Basel, Switzerland","Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba-Geigy Limited, Oncology and Virology Department, Basel, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jean-Michel Cardot","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jean-Michel Cardot","raw_affiliation_strings":["Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010136394","display_name":"Christian Schnell","orcid":"https://orcid.org/0000-0001-5646-4654","observed_orcids":["https://orcid.org/0000-0001-5646-4654"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christian Schnell","raw_affiliation_strings":["Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064300160","display_name":"Peter van Hoogevest","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Van Hoogevest","raw_affiliation_strings":["Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043369263","display_name":"Daniel Gygax","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel Gygax","raw_affiliation_strings":["Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ciba-Geigy Limited, Oncology and Virology Department, Pharmaceuticals Division, K-125.4.17, CH-4002 Basel, Switzerland","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5083980759"],"corresponding_institution_ids":[],"apc_list":{"value":3620,"currency":"USD","value_usd":3620},"apc_paid":null,"fwci":1.5019,"has_fulltext":false,"cited_by_count":22,"citation_normalized_percentile":{"value":0.80173595,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"82","issue":"10","first_page":"997","last_page":"1001"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9214000105857849,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.9214000105857849,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.018400000408291817,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.014399999752640724,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liposomal-drug-delivery","display_name":"liposomal drug delivery","score":0.8650000095367432},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8840000033378601},{"id":"https://openalex.org/keywords/liposome-clearance","display_name":"liposome clearance","score":0.9290000200271606},{"id":"https://openalex.org/keywords/elimination-kinetics","display_name":"elimination kinetics","score":0.6079999804496765},{"id":"https://openalex.org/keywords/plasma-drug-concentration","display_name":"plasma drug concentration","score":0.47099998593330383},{"id":"https://openalex.org/keywords/rats","display_name":"rats","score":0.3779999911785126},{"id":"https://openalex.org/keywords/dogs","display_name":"dogs","score":1.0}],"concepts":[{"id":"https://openalex.org/C185154212","wikidata":"https://www.wikidata.org/wiki/Q410454","display_name":"Liposome","level":2,"score":0.8831791877746582},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8731294870376587},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8104588985443115},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.645473301410675},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.5257395505905151},{"id":"https://openalex.org/C43376680","wikidata":"https://www.wikidata.org/wiki/Q6580786","display_name":"Bolus (digestion)","level":2,"score":0.4861292839050293},{"id":"https://openalex.org/C77281830","wikidata":"https://www.wikidata.org/wiki/Q718608","display_name":"Dosage form","level":2,"score":0.44005587697029114},{"id":"https://openalex.org/C2779216040","wikidata":"https://www.wikidata.org/wiki/Q410387","display_name":"Ethanolamine","level":2,"score":0.4364081025123596},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.18071851134300232},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17352113127708435},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12996655702590942}],"mesh":[{"descriptor_ui":"D000119","descriptor_name":"Acetylmuramyl-Alanyl-Isoglutamine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000119","descriptor_name":"Acetylmuramyl-Alanyl-Isoglutamine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000119","descriptor_name":"Acetylmuramyl-Alanyl-Isoglutamine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000119","descriptor_name":"Acetylmuramyl-Alanyl-Isoglutamine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004285","descriptor_name":"Dogs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004337","descriptor_name":"Drug Carriers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008081","descriptor_name":"Liposomes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010714","descriptor_name":"Phosphatidylethanolamines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D010714","descriptor_name":"Phosphatidylethanolamines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D010714","descriptor_name":"Phosphatidylethanolamines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011919","descriptor_name":"Rats, Inbred Strains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/jps.2600821005","doi":"https://doi.org/10.1002/jps.2600821005","is_oa":false,"landing_page_url":"https://doi.org/10.1002/jps.2600821005","pdf_url":null,"source":{"id":"https://openalex.org/S130661733","display_name":"Journal of Pharmaceutical Sciences","issn_l":"0022-3549","issn":["0022-3549","1520-6017"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Sciences","raw_type":"journal-article"},{"id":"pmid:8254500","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8254500","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of pharmaceutical sciences","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8048999905586243,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":28,"referenced_works":["https://openalex.org/W631301279","https://openalex.org/W1494989386","https://openalex.org/W1518016665","https://openalex.org/W1546024914","https://openalex.org/W1560442904","https://openalex.org/W1851781734","https://openalex.org/W1868696300","https://openalex.org/W1963895695","https://openalex.org/W1964149427","https://openalex.org/W1971038787","https://openalex.org/W1989927329","https://openalex.org/W2020067635","https://openalex.org/W2030063071","https://openalex.org/W2034084029","https://openalex.org/W2035504671","https://openalex.org/W2050521315","https://openalex.org/W2055771367","https://openalex.org/W2060206902","https://openalex.org/W2063267366","https://openalex.org/W2114013702","https://openalex.org/W2122683880","https://openalex.org/W2125210221","https://openalex.org/W2125897033","https://openalex.org/W2133756116","https://openalex.org/W2326324348","https://openalex.org/W2800782238","https://openalex.org/W2866200512","https://openalex.org/W4246025413"],"related_works":["https://openalex.org/W2048629831","https://openalex.org/W1560442904","https://openalex.org/W1993008784","https://openalex.org/W1971860261","https://openalex.org/W2082835769","https://openalex.org/W2187193315","https://openalex.org/W2166426919","https://openalex.org/W2041021629","https://openalex.org/W1879456487","https://openalex.org/W2375535244"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}